iCAD

iCAD is a global medical technology company that applies artificial intelligence to cancer detection, with particular focus on breast cancer screening and diagnosis. Founded in 1984 and headquartered in Nashua, New Hampshire, the company develops machine learning and computer vision systems used by healthcare providers to identify cancer more accurately, reliably and quickly. Its technical work spans radiology AI, mammography AI, automated breast density assessment and personalised short-term risk evaluation.

The company's flagship product, the ProFound Breast Health Suite, is a portfolio of AI technologies for breast cancer detection, automated density assessment and short-term risk evaluation. The technologies sit within clinical workflows that have read more than 40 million mammograms worldwide, with nearly 30% of those exams being tomosynthesis.

iCAD operates in over 50 countries and works across the medical technology, radiology, diagnostic imaging and oncology sectors. Its stated mission, "creating a world where cancer can't hide", frames a broader goal of democratising access to AI-powered mammography and improving early detection and patient outcomes.